Fred Hutch Cancer Center | Strategic Alliance Partners

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss findings from a Q-TWiST analysis of the CheckMate 649 trial in advanced gastric/GEJ cancer.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.

August 13, 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy has affected the treatment paradigm for upper gastrointestinal cancers.

August 12, 2024

Mazyar Shadman, MD, MPH, discusses the investigation of sonrotoclax in the CELESTIAL-TNCLL trial in treatment-naïve chronic lymphocytic leukemia.

August 07, 2024

Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.

August 06, 2024

Rahul Banerjee, MD, FACP, discusses key takeaways from his presentation at an OncLive State of the Science Summit on multiple myeloma.

July 31, 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss ongoing trials and future treatment directions for chronic lymphocytic leukemia.

July 31, 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss real-world safety data for BTK inhibitors in chronic lymphocytic leukemia from EHA 2024.

July 31, 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss matching-adjusted indirect comparisons of BTK inhibitors in chronic lymphocytic leukemia.

July 31, 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss findings from the SEQUOIA trial of zanubrutinib in treatment-naive chronic lymphocytic leukemia.

July 31, 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, discuss how to use data for BTK inhibitors to inform clinical decisions in chronic lymphocytic leukemia.

July 31, 2024

Marc S. Hoffmann, MD, and Mazyar Shadman, MD, MPH, on factors for selecting a BTK inhibitor or a venetoclax-based regimen in chronic lymphocytic leukemia.

July 22, 2024

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

June 21, 2024

MB-106 showcased a favorable safety profile and elicited responses in heavily pretreated patients with refractory Waldenström macroglobulinemia.

June 17, 2024

Petros Grivas, MD, PhD, and Chandler H. Park, MD, FACP, discuss key updates in genitourinary cancer on OncLive News Network: On Location.

June 14, 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.

June 14, 2024

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses prognosis and rarity of patients with NRG1 fusion–positive pancreatic cancer.

June 06, 2024

Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.

May 30, 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in May 2024.

May 28, 2024

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.